Lido Advisors LLC Buys New Stake in Twist Bioscience Corporation $TWST

Lido Advisors LLC bought a new stake in Twist Bioscience Corporation (NASDAQ:TWST) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 42,240 shares of the company’s stock, valued at approximately $8,162,000.

Other large investors also recently added to or reduced their stakes in the company. E. Ohman J or Asset Management AB acquired a new stake in shares of Twist Bioscience in the second quarter valued at $853,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Twist Bioscience in the 1st quarter valued at $22,563,000. Bank of America Corp DE raised its holdings in shares of Twist Bioscience by 46.3% in the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock valued at $27,764,000 after buying an additional 184,907 shares during the period. William Blair Investment Management LLC acquired a new position in Twist Bioscience during the 2nd quarter worth about $223,722,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Twist Bioscience during the 2nd quarter worth about $8,215,000.

Recent Twist Bioscience Headlines

Investors following TWST have been watching these headlines:

• Positive Sentiment: Fiscal fourth-quarter revenue rose 28% year over year to $126.6 million, ahead of analyst expectations. The quarterly loss of $0.32 per share was also narrower than estimates and improved from a $0.45 loss a year earlier. Article: Twist Bioscience Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: AI drug discovery generated $59.1 million in fiscal 2026, highlighting a growing business area for the company. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million was only slightly above the $549 million consensus. Reports characterized the outlook as insufficient to satisfy investors, helping explain why the stock fell despite the quarterly beats. Article: Twist Bio Slips Despite Q4 Beat After Underwhelming FY27 Outlook

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Canaccord Genuity Group set a $150.00 target price on Twist Bioscience in a report on Friday. Leerink Partners boosted their price target on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. UBS Group initiated coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target on the stock. Piper Sandler increased their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group began coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $148.00.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 356,546 shares of the company’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the sale, the chief executive officer owned 620,589 shares in the company, valued at $98,046,856.11. This represents a 36.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 10,088 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the completion of the sale, the senior vice president directly owned 106,632 shares in the company, valued at $20,140,652.16. This represents a 8.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 495,279 shares of company stock valued at $80,489,387. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $114.22 on Friday. The company has a fifty day simple moving average of $150.57 and a two-hundred day simple moving average of $92.73. The company has a market cap of $7.16 billion, a price-to-earnings ratio of -51.45 and a beta of 2.25. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The business had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. Twist Bioscience’s revenue was up 26.7% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.11 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.